OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction

About this update from Osr Holdings, Inc.

Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company focused on innovative therapeutics and healthcare technologies, today announced it has entered into a definitive Asset Purchase Agreement ("APA") with VAXIMM AG ("Vaximm") to acquire the full global intellectual property portfolio and related assets for an aggregate purchase price of $30 million. The acquisition follows OSRH's previously announced definitive global exclusive license agreement with BCM Europe AG ("BCME") for VXM01, which includes up to $815 million in milestone payments tied to the development and commercialization of the program. Under the APA, OSRH will acquire the complete VXM01 intellectual property portfolio, including: The VXM01 IP portfolio includes issued and pending patent protection across major global jurisdictions including the United States, Canada, Europe, Japan, China, Korea, and additional territories, with protection extending into 2038. "This acquisition advances our strategy of centralizing high-value intellectual property assets at the OSRH parent level," said Peter Hwang, CEO of OSRH. "Under our hub-and-spoke operating model, OSRH acts as the central IP owner, while development and commercialization are executed through affiliated entities and partners. This enhances licensing flexibility and long-term royalty economics, with value accruing to OSRH shareholders." As previously disclosed, OSRH entered into a definitive global exclusive license agreement with BCME on April 29, 2026 relating to the development, commercialization and potential sublicensing of VXM01. Under the agreement: Under the terms of the APA, the $30 million purchase price becomes payable upon the first milestone event under the BCME License Agreement, defined as completion of a Phase 2 clinical study (Phase 2b or equivalent trial pending discussions) of VXM01 in either glioblastoma (GBM) or pancreatic ductal adenocarcinoma (PDAC). The agreement also permits OSRH to make voluntary partial payments prior to such milestone event. The centralized IP ownership structure may also facilitate future evaluation of innovative financing and royalty participation structures associated with the VXM0...

View stock analysis, news, and events for Osr Holdings, Inc.